AstraZeneca updates total voting rights count

AstraZeneca PLC has reported an updated share count for voting purposes.

Accepted by SEC EDGAR 06/01/2026 - 10:06 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AstraZeneca PLC has reported an updated share count for voting purposes. As at 31 May 2026, the company’s issued share capital with voting rights consists of 1,551,009,750 ordinary shares of US$0.25 each. The company holds no shares in treasury, so the total number of voting rights is also 1,551,009,750.

This figure is provided under the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1 and is intended to help shareholders calculate whether they must notify AstraZeneca and regulators about their holdings or changes in their holdings.

Key Figures

Total voting rights: 1,551,009,750 Ordinary shares in issue with voting rights: 1,551,009,750 shares Nominal value per ordinary share: US$0.25 +1 more

4 metrics

Total voting rights 1,551,009,750 Total number of voting rights as at 31 May 2026

Ordinary shares in issue with voting rights 1,551,009,750 shares Issued share capital of US$0.25 ordinary shares as at 31 May 2026

Nominal value per ordinary share US$0.25 Par value of each AstraZeneca ordinary share

Treasury shares held 0 shares Treasury position as at 31 May 2026

Key Terms

Total Voting Rights, Disclosure and Transparency Rule 5.6.1, issued share capital, Treasury, +1 more

5 terms

Total Voting Rights financial

"1 June 2026 Total Voting Rights The following notification is made"

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Disclosure and Transparency Rule 5.6.1 regulatory

"made in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1"

issued share capital financial

"As at 31 May 2026 the issued share capital of AstraZeneca PLC"

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

Treasury financial

"No shares are held in Treasury."

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

voting rights financial

"Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,009,750."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did AstraZeneca (AZN) report as of 31 May 2026?

AstraZeneca reported 1,551,009,750 total voting rights as of 31 May 2026. This equals its issued share capital with voting rights and is used by investors for ownership disclosure calculations.

How many AstraZeneca (AZN) ordinary shares with voting rights are in issue?

AstraZeneca has 1,551,009,750 ordinary shares of US$0.25 in issue with voting rights. This number matches the company’s total voting rights because no shares are held in treasury.

Does AstraZeneca (AZN) hold any treasury shares as of 31 May 2026?

No, AstraZeneca holds no shares in treasury as of 31 May 2026. Because there are no treasury shares, the total number of voting rights equals the total issued share capital with voting rights.

Why is AstraZeneca (AZN) disclosing its total voting rights?

AstraZeneca is disclosing total voting rights to comply with Disclosure and Transparency Rule 5.6.1. Shareholders use this figure as the denominator when assessing whether they must notify their interests or changes in interests.

What is the nominal value of AstraZeneca (AZN) ordinary shares?

AstraZeneca’s ordinary shares have a nominal value of US$0.25 each. There are 1,551,009,750 such shares with voting rights in issue as of 31 May 2026, establishing the company’s voting capital base.

Who signed the AstraZeneca (AZN) total voting rights notification?

The notification was signed by Matthew Bowden, Company Secretary of AstraZeneca PLC. It was executed on behalf of the company under the requirements of the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights

1 June 2026

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,009,750.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 June 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary